Hidradenitis Suppurativa: A Systematic Review and Meta-analysis of Therapeutic Interventions

Tchero, Huidi; Herlin, Christian; Bekara, Farid; Fluieraru, Sergiu; Téot, Luc

doi:10.4103/ijdvl.ijdvl_69_18

Cited by 50 publications

(46 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results of quantitative meta-analysis supported the findings of a previous review conducted by Tchero et al [ 10 ] Furthermore, we assumed that the true effect of adalimumab in treating moderate-to-severe HS varies from 1 study to another, owing to the different loading doses and pharmacological effects between individuals. Therefore, we considered the random-effect model is more suitable for pooled effect size estimation.…”

Section: Discussionsupporting

confidence: 90%

“…[ 8 ] Previous systematic reviews and meta-analyses have concluded that adalimumab administered weekly is effective in treating HS and that it caused only tolerable adverse events (AEs). [ 9 , 10 ] However, the effects of adalimumab in patients achieving clinical responses have not been clarified, although the results of new trials have been published. Therefore, here, we performed a meta-analysis of randomized controlled trials (RCTs) with trial sequential analysis (TSA) to assess the efficacy and safety of adalimumab compared with those of a placebo for the treatment of HS.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of adalimumab in hidradenitis suppurativa

Huang

Chen

2021

Medicine

View full text Add to dashboard Cite

Background: Adalimumab is used as a first-line biologic agent in the management of moderate-to-severe hidradenitis suppurativa (HS). The objective of the present study was to evaluate the efficacy and safety of adalimumab in patients with moderate-to-severe HS. Methods: We performed a systematic review and meta-analysis according to Preferred Reporting Items for Systematic reviews and Meta-Analysis guidelines. Pooled estimates, namely standardized mean difference (SMD) and relative risk (RR), were calculated using random-effect model with trial sequential analysis. Small study effects were examined using the Doi plot. Certainty of evidence (CoE) was assessed using “The Grading of Recommendations Assessment, Development, and Evaluation” approach, and number-needed-to-treat (NNT) was calculated. Results: Five randomized controlled trials, involving 1014 patients, were included. We performed subgroup analysis of adalimumab administered subcutaneously both weekly and every other week. Adalimumab administered weekly was associated with better clinical response achievement (RR 1.76, 95% confidence interval [95% CI] 1.35–2.29; trial sequential analysis TSA-adjusted CI 1.01–3.08; CoE: low; NNT = 5) and a significant improvement in modified Sartorius score (SMD = −0.45, 95% CI = −0.76 to −0.13; CoE: very low; NNT = 10) and dermatology life quality index (DLQI) (SMD −0.47, 95% CI −0.61 to −0.32; CoE: low; NNT = 10). Nevertheless, adalimumab administered every other week showed an improvement only in modified Sartorius score. The pooled RRs of adverse events in both groups revealed no statistical significance when compared with the placebo. Conclusions: Adalimumab administered weekly resulted in not only better clinical responses than placebo but also significantly improved disease severity and quality of life of patients with moderate-to-severe HS. Our study provides supporting evidence to the current guidelines and aids decision-making in the application of adalimumab in HS management.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of adalimumab in hidradenitis suppurativa

Huang

Chen

2021

Medicine

View full text Add to dashboard Cite

show abstract

“…1 However, treatment steadily is founded on physician clinical expertise instead of research evidence 3 since these treatment modalities are vastly imperfect, and additional studies are required to inaugurate the most effective treatment guidance. 7 Forasmuch as the medical treatment takes long time to function, surgery in contrast presents instant improvement, 6 and it is considered the only approach with curative potential 3 mainly in the advanced cases, 8 even 166 years post its first description by Verneuil. 4 Surgical approach ranges from simple incision and drainage to local or wide excision.…”

Section: Discussionmentioning

confidence: 99%

“…However, treatment steadily is founded on physician clinical expertise instead of research evidence‎ 3 since these treatment modalities are vastly imperfect, and additional studies are required to inaugurate the most effective treatment guidance. 7 …”

Section: Discussionmentioning

confidence: 99%

A Novel Technique for the Treatment of a Case of Verneuil's Disease of Perineum and Axillary Regions

et al. 2021

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic inflammatory disease involving apocrine glands of the skin. It carries out an important burden on the daily life of the patient. Unfortunately, it presents a major concern for medical care management in the absence of clear guidelines for proper medical and surgical treatment. Hence, we report a case of concomitant axillary and perianal HS. We opted for surgical management using a novel technique, which proved efficacy for a year of follow-up recurrence free.

show abstract

“…The prevalence of HS is 0.05 -4.1% (1). Numerous treatment strategies are available for HS, such as antibiotics, retinoids, anti-androgens, immunosuppressive, anti-inflammatory agents, adalimumab (anti-tumor necrosis factor antibody), radiotherapy, surgery, and laser, but none is very satisfactory (2,3). Combination therapy with antibiotics and hyperbaric oxygen have shown promising results (3).…”

mentioning

confidence: 99%

Therapeutic Pearl: The Role of Sodium Hypochlorite in the Treatment of Chronic Hidradenitis Suppurativa

Mukhtar¹

2021

Mod Care J

View full text Add to dashboard Cite

Hidradenitis Suppurativa: A Systematic Review and Meta-analysis of Therapeutic Interventions

Cited by 50 publications

References 2 publications

Efficacy and safety of adalimumab in hidradenitis suppurativa

Efficacy and safety of adalimumab in hidradenitis suppurativa

A Novel Technique for the Treatment of a Case of Verneuil's Disease of Perineum and Axillary Regions

Therapeutic Pearl: The Role of Sodium Hypochlorite in the Treatment of Chronic Hidradenitis Suppurativa

Contact Info

Product

Resources

About